China is outsourcing choice in complex Asian market
This article was originally published in Scrip
Executive Summary
China will lead the growth in Asia's pharmaceutical markets, driven by low costs, strong market potential, foreign investment and increased contract research and manufacturing. Outsourcing activities both there and across Asia will move towards high-end drug discovery as the region's capabilities develop, a new report from PricewaterhouseCoopers(PwC) predicts.